Common Side Effects of Keytruda in Breast Cancer Treatment
Keytruda (pembrolizumab), used in triple-negative breast cancer often with chemotherapy like paclitaxel and doxorubicin, causes immune-related side effects from T-cell activation. These include fatigue (up to 50% of patients), nausea (40%), rash (30%), diarrhea (25%), hypothyroidism (15%), and severe issues like pneumonitis (3-5%), colitis, hepatitis, or endocrinopathies.[1][2]
Monitoring and Early Detection Strategies
Regular checks catch issues early. Labs every 3 weeks track thyroid function (TSH, free T4), liver enzymes (ALT/AST), kidney function (creatinine), and blood counts. Lung imaging or symptoms like cough prompt CT scans for pneumonitis. Patients log symptoms daily via apps or journals for oncologist review.[2][3]
Managing Skin Reactions and Rashes
Topical steroids like hydrocortisone cream handle mild rashes; oral prednisone (0.5-1 mg/kg/day) for moderate cases, tapered over weeks. Antihistamines (e.g., cetirizine) reduce itch. Avoid irritants; use fragrance-free moisturizers. Severe cases may pause Keytruda.[2][4]
Handling Gastrointestinal Issues Like Diarrhea and Colitis
Loperamide (Imodium) starts at 4 mg then 2 mg after each loose stool for mild diarrhea. Budesonide (9 mg/day) or prednisone for colitis; infliximab (5 mg/kg IV) if steroids fail. Hold Keytruda if grade 3+; endoscopy confirms diagnosis.[2][3]
Addressing Endocrine Problems Such as Hypothyroidism or Adrenal Issues
Levothyroxine replaces thyroid hormone for hypothyroidism; dose adjusts via TSH levels. Hydrocortisone for adrenal insufficiency. Most resolve with hormone therapy; Keytruda often continues.[2][4]
Respiratory Side Effects: Pneumonitis Prevention and Treatment
High-dose steroids (1-2 mg/kg prednisone) for confirmed pneumonitis; taper slowly with lung function tests. Prophylactic budesonide in high-risk patients reduces incidence. Permanent Keytruda discontinuation for grade 3+ cases.[1][3]
Fatigue and General Supportive Care
Rest, balanced nutrition, and light exercise (walking) help fatigue. Erythropoietin avoided due to cancer risks. Anti-nausea meds like ondansetron pair with chemotherapy. Multidisciplinary teams (oncologists, endocrinologists, dermatologists) coordinate via tumor boards.[2][4]
When to Hold or Stop Keytruda
Per FDA guidelines, hold for grade 2 side effects unresponsive to treatment; resume if grade 0-1. Discontinue permanently for grade 4 or recurrent grade 3 (e.g., any organ). Breast cancer trials (KEYNOTE-522) show 15% discontinuation rate due to toxicity.[1][2]
Patient Tips for Daily Management
Stay hydrated, report new symptoms within 24 hours, carry steroid cards, and join support groups like those from Susan G. Komen. Vaccinations (non-live) before starting; avoid during therapy.[3][4]
Sources
[1]: FDA Keytruda Label
[2]: KEYNOTE-522 Trial (NEJM)
[3]: NCCN Breast Cancer Guidelines
[4]: ASCO Management Guidelines for Immune Checkpoint Inhibitors